Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
Open Access
- 7 July 2021
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (2S), 4534
- https://doi.org/10.15829/1560-4071-2021-4534
Abstract
The review is devoted to the clinical efficacy of sodium-glucose cotransporter type 2 (SGLT2) inhibitors. Information on the mechanisms of drug action is given, as well as rationale for their use in the management of patients with diabetes and heart failure (HF) is provided. The results of large-scale randomized clinical trials evaluating the efficacy of SGLT2 inhibitors are discussed. We showed the beneficial effect of SGLT-2 inhibitors on the risk of cardiovascular events in patients with type 2 diabetes. In addition, an evidence of the ability of dapagliflozin and empagliflozin to improve the prognosis of patients with HF with reduced ejection fraction without diabetes are presented. The evidence and mechanisms of the nephroprotective action of SGLT2 inhibitors in patients with diabetes and HF are considered.Keywords
This publication has 53 references indexed in Scilit:
- The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 DiabetesClinical Therapeutics, 2015
- The Bi-directional Impact of Two Chronic Illnesses: Heart Failure and Diabetes – A review of the Epidemiology and OutcomesCardiac Failure Review, 2015
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes MellitusDrugs, 2014
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusThe New England Journal of Medicine, 2013
- Diabetes, left ventricular systolic dysfunction, and chronic heart failureEuropean Heart Journal, 2008
- Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeEuropean Heart Journal, 2008
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Influence of diabetes on the survival of patients hospitalized with heart failure: A 12‐year studyEuropean Journal of Heart Failure, 2005
- Risk Factors for Congestive Heart Failure in US Men and WomenArchives of Internal Medicine, 2001
- Role of diabetes in congestive heart failure: The Framingham studyThe American Journal of Cardiology, 1974